US4464377A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti-thrombotic therapeutic compositions
Assignee: Sanofi Aventis France
•
Filing: 1981-08-12
•
Granted: 1984-08-07
•
Expires: 2001-08-12
Abstract
Abstract This invention relates to therapeutic compositions comprising, as active ingredients, a combination of a pyridine derivative having an anti-blood-platelet-aggregation activity with a derivative having beta-blocking properties, which exhibit synergistic anti-thrombotic activity.
Inventors
- 👤 Jean Blanchard
- 👤 Edouard Panak
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 13:25
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
129 words
A prophylactic and therapeutic anti-thrombotic composition comprising a biologically acceptable carrier and an effective amount of the combination of a compound having beta-blocking properties and ticlopidine or the pharmaceutically acceptable salts thereof, said beta-blocking compounds being selected from the group consisting of a compound of the formula: ##STR9## in which: R 2 is selected from the group consisting of phenyl, naphthyl, indanyl, fluorene, morpholinyl, pyridyl, pyrimidyl, indolyl, quinolyl and the mercapto, acyl, carboxy, nitro or amino substituted groups thereof, R 3 is selected from the group consisting of hydrogen, lower alkanoyl and benzoyl, R 4 is selected from the group consisting of lower alkyl, cycloloweralkyl, and phenyl lower alkyl, and R 5 is selected from the group consisting of hydrogen and lower alkyl; and the pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim
129 words
A prophylactic and therapeutic anti-thrombotic composition comprising a biologically acceptable carrier and an effective amount of the combination of a compound having beta-blocking properties and ticlopidine or the pharmaceutically acceptable salts thereof, said beta-blocking compounds being selected from the group consisting of a compound of the formula: ##STR9## in which: R 2 is selected from the group consisting of phenyl, naphthyl, indanyl, fluorene, morpholinyl, pyridyl, pyrimidyl, indolyl, quinolyl and the mercapto, acyl, carboxy, nitro or amino substituted groups thereof, R 3 is selected from the group consisting of hydrogen, lower alkanoyl and benzoyl, R 4 is selected from the group consisting of lower alkyl, cycloloweralkyl, and phenyl lower alkyl, and R 5 is selected from the group consisting of hydrogen and lower alkyl; and the pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
27 words
The composition of claim 1 wherein said beta-blocking compound is selected from the group consisting of: 1-isopropylamino-3-[(1)-naphthyloxy]-2-propanol; (±)1-isopropylamino-3-[4-(2-methoxy-ethyl)-phenoxy]-2-propanol; 2-[4-(2-hydroxy-3-isopropylamino-propoxy)-phenyl]acetamide; 3'-acetyl-4'-(2-hydroxy-3-isopropylamino-propoxy)-butyranilide; 1-(4-indolyl-oxy)-3(isopropylamino)-2-propanol; (-)-1-tert-butylamino)-3-[3-(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol; 1-(tert-butylamino)-3-(2-chloro-5-methyl-phenoxy)-2-propanol; (±)-5-[3-tert-butylamino)-2-hydroxy-propoxy]3,4-dihydro-2H-naphthalenone 1-(2'-allyl-phenoxy)-3-isopropylamino-2-propanol; and 1-(2-allyloxy-phenoxy)-3-isopropylamino-2-propanol.
Claim 4
Dependent Claim
25 words
The composition of claim 1 wherein said beta-blocking compound is selected from the group consisting of: 2-isopropylamino-1-(1-naphthyl)-ethanol; 2-tert-butylamino-1-(2,5-dimethoxy-phenyl)-ethanol; 1-(3,4-dichlorophenyl)-2-isopropylamine-ethanol; 2-isopropylamino-1-(4-nitro-phenyl)-propanol; 1-(4-carbamoyl-3-hydroxyphenyl)-2-tert-butylamino-ethanol; and 2-tert-butylamino-1-(1,2,3,4-tetrahydro-5-naphthyl)-ethanol or 2-isopropylamino-1-(methylsulfonylaminophenyl)-ethanol.
Claim 5
Dependent Claim
17 words
The composition of any one of claims 2 or 3 wherein the ticlopidine is a hydrochloride salt.
Claim 6
Dependent Claim
25 words
The composition of claim 1 containing about 0.05 to about 0.2 g of ticlopidine and about 0.01 to about 0.15 g of said beta-blocking compound.
Claim 7
Independent Claim
44 words
A method for the prevention or treatment of thrombosis in a patient which comprises administering to said patient in an amount effective to prevent or treat such thrombosis, an effective amount of the composition of any one of claims 2, 3, 5 or 1.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-08-07 | 1988-02-06 | 1988-08-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-08-07 | 1992-02-06 | 1992-08-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-08-07 | 1996-02-06 | 1996-08-07 | $7700.00 | Window Closed / Lapsed |